Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

2.87
-0.1000-3.37%
Post-market: 3.130.2600+9.06%19:56 EDT
Volume:42.18K
Turnover:124.06K
Market Cap:48.59M
PE:-0.06
High:3.00
Open:2.90
Low:2.87
Close:2.97
52wk High:20.99
52wk Low:2.87
Shares:16.93M
Float Shares:2.07M
Volume Ratio:0.79
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-48.7183
EPS(LYR):-52.5900
ROE:-59.28%
ROA:-19.90%
PB:-1.75
PE(LYR):-0.05

Loading ...

Transcode Therapeutics Says DEFJ LLC Files Initial Beneficial Ownership Statement

Reuters
·
Aug 06

TransCode Therapeutics Updates Preferred Stock Governance Terms

TIPRANKS
·
Aug 04

TransCode Therapeutics Shareholders Approve Key Capital Measures

TIPRANKS
·
Jul 21

Transcode Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 21

TransCode Therapeutics Updates Preferred Stock Ownership Limits

TIPRANKS
·
Jul 18

Transcode Therapeutics Adjourns Annual Shareholder Meeting to July 20 Pending NASDAQ Review

Reuters
·
Jul 03

TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms

Reuters
·
Jun 18

TransCode Highlights Progress of Lead RNA Cancer Therapeutic

TIPRANKS
·
Jun 18

TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a

MT Newswires Live
·
Jun 03

TransCode Therapeutics reports Phase 1a trial of TTX-MC138 meets safety endpoint in metastatic cancer

Reuters
·
Jun 03

Transcode Therapeutics - Ttx-Mc138 Advances to Phase 2a Clinical Development in Ctdna-Positive Colorectal Cancer

THOMSON REUTERS
·
Jun 03

Transcode Therapeutics - Phase 1a Trial Meets Safety Endpoint With No Dose-Limiting Toxicities

THOMSON REUTERS
·
Jun 03

Transcode Therapeutics - Recommended Phase 2a Dose for Ttx-Mc138 Set at 4.8Mg/Kg

THOMSON REUTERS
·
Jun 03

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

Benzinga_recent_news
·
Jun 03

TransCode Sets Key Deadlines for 2026 Shareholder Meeting

TIPRANKS
·
Jun 01

TransCode Therapeutics sets 2026 annual shareholder meeting

Reuters
·
Jun 01

Transcode Therapeutics initiates Phase 2a clinical trial with TTX-MC138

TIPRANKS
·
May 27

TransCode Therapeutics launches Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer patients

Reuters
·
May 27

Transcode Therapeutics Initiates Phase 2a Clinical Trial With Ttx-Mc138 in Patients With Ctdna Positive Colorectal Cancer

THOMSON REUTERS
·
May 27

TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice

TIPRANKS
·
May 23